BJPsych Open 2017 May 9;3(3):154-158. Epub 2017 Jun 9.
, MD, FRCPsych, Departments of Psychiatry, Neurology, and Anaesthesiology, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
Download full-text PDF
BJPsych Open 2016 Nov 1;2(6):341-345. Epub 2016 Nov 1.
, BAppSci, Perth Clinic, West Perth, Western Australia; School of Psychology, The University of Western Australia, Crawley, Australia.
Background: Routine symptom monitoring and feedback improves out-patient outcomes, but the feasibility of its use to inform decisions about discharge from in-patient care has not been explored.
Aims: To examine the potential value to clinical decision-making of monitoring symptoms during psychiatric in-patient hospitalisation.
Method: A total of 1102 in-patients in a private psychiatric hospital, primarily with affective and neurotic disorders, rated daily distress levels throughout their hospital stay. Read More
BJPsych Open 2016 Nov 14;2(6):390-393. Epub 2016 Dec 14.
, MBBS, SFHEA, PhD, FRCPsych, National Psychosis Unit, South London and Maudsley NHS Foundation Trust, London, UK; National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, King's College London, London, UK; Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Background: There is currently limited experience in the initiation and maintenance of clozapine for treatment-resistant psychosis in adults with established structural heart disease. These complex patients require close supervision and liaison between colleagues. Here we present the successful experience of treating one such patient within our service and describe a monitoring plan to ensure that these treatments can be provided both safely and effectively. Read More
BJPsych Open 2016 May 22;2(3):244-246. Epub 2016 Jun 22.
, MBBS, SFHEA, PhD, FRCPsych, National Psychosis Unit, Bethlem Royal Hospital, London, UK.
Summary: A case is presented of a 25-year-old man with treatment-resistant paranoid schizophrenia whose only previous trial of clozapine had been stopped following a suspected clozapine-induced myocarditis. Due to the failure of his psychosis to respond to a number of antipsychotic treatments and augmentation strategies, clozapine was restarted on admission. His rechallenge was marked by intermittent pyrexia, tachycardia and elevated C-reactive protein (CRP), but eosinophilia was absent. Read More
BJPsych Open 2017 Jan 9;3(1):22-25. Epub 2017 Feb 9.
, BSc MBBS SFHEA PhD FRCPsych, National Psychosis Unit, South London and Maudsley NHS Foundation Trust, London, UK; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, London, UK.
A case is presented of a 30-year-old female with treatment-resistant schizoaffective disorder who was referred to a tertiary-level specialist psychosis service. We describe the history of clozapine trials and associated episodes of agranulocytosis and neutropenia, followed by the successfully tolerated third clozapine re-challenge within our service.
Declaration Of Interest: None. Read More